EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Initiation and Maintenance of Low‐Dose Transdermal Testosterone in Non‐Binary Individuals: A Retrospective Audit

Eli Ward-Smith, Ada S Cheung, Peter Locke, Sav Zwickl, Brendan J Nolan iD

Clinical Endocrinology · 2026

DOI: 10.1111/cen.70110 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Endocrinology, 2026. Verfasst von Eli Ward-Smith und 4 weiteren Autor:innen. Beteiligte Einrichtung: Trans Health Research Group, The University of Melbourne, Melbourne, Australia. Hauptthemen laut MEDLINE: Testosterone. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Royal Australasian College of Physicians-Endocrine Society of Australia Research Establishment Fellowship and a National Health and Medical Research Council In…, National Health and Medical Research Council Investigator, National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

An increasing number of trans individuals, particularly those who are non‐binary, desire lower testosterone doses than those outlined in current guidelines for gender affirmation. These guidelines acknowledge the need for a tailored approach to treatment, especially for non‐binary people. However, existing guidelines for initiation of testosterone assume that trans individuals desire rapid and complete masculinisation through standard dosing. We aimed to assess the initiation and maintenance of low‐dose testosterone in non‐binary individuals treated with transdermal testosterone for ≥ 6 months.

Design

Retrospective audit. Patients Non‐binary individuals initiating low‐dose transdermal testosterone with ≥ 6 months follow‐up.

Intervention

Testosterone 1% gel (< 50 mg daily) or testosterone 5% cream (< 100 mg daily).

Measurements

Transdermal testosterone dose and serum total testosterone concentration.

Results

Forty‐six individuals were included. Median age was 27 years (24−30) and duration of testosterone was 14 months (9−24). For individuals treated with testosterone 1% gel, median dose at initiation was 12.5 mg (12.5−25) and 25 mg (20.4−37.5) at last follow‐up ( p < 0.01), and for those treated with testosterone 5% cream, the median dose at initiation was 50 mg (31.3−50) and 50 mg (50−68.8) at last follow‐up ( p = 0.02). Median serum total testosterone concentration was 11 nmol/L (5.2−15.7). By the last follow‐up, 40 (87%) remained on low‐dose testosterone and 6 (13%) had increased to full‐dose testosterone. In a subgroup of 30 individuals with ≥ 12 months treatment, 26 (87%) remained on low‐dose testosterone by last follow‐up. Three (7%) individuals had polycythemia (haematocrit > 0.5).

Conclusions

Most non‐binary individuals initiating low‐dose transdermal testosterone continue doses lower than those recommended in current guidelines after 6−12 months of treatment. These hypothesis‐generating findings highlight the need for studies evaluating the influence of low‐dose testosterone on clinical outcomes and safety end‐points.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TestosteroneHumansRetrospective StudiesMaleAdultAdministration, CutaneousFemaleGender-Nonconforming PersonsYoung AdultTransgender Persons

Stichwörter der Autor:innen

gender identitynon‐binarytestosteronetransdermaltransgender

Substanzen

Testosterone

Autor:innen und Institutionen

  • Trans Health Research Group, The University of Melbourne, Melbourne, Australia.
  • Department of Endocrinology, Austin Health, Melbourne, Australia.
  • Equinox Gender Diverse Clinic, Thorne Harbour Health, Abbotsford, Victoria, Australia.

ORCID-Profile: Brendan J Nolan

Förderung

  • Royal Australasian College of Physicians-Endocrine Society of Australia Research Establishment Fellowship and a National Health and Medical Research Council In…
  • National Health and Medical Research Council Investigator
  • National Health and Medical Research Council

Zitieren

APA

Ward-Smith, E., Cheung, A. S., Locke, P., Zwickl, S., & Nolan, B. J. (2026). Initiation and Maintenance of Low‐Dose Transdermal Testosterone in Non‐Binary Individuals: A Retrospective Audit. Clinical Endocrinology. https://doi.org/10.1111/cen.70110

Vancouver

Ward-Smith E, Cheung AS, Locke P, Zwickl S, Nolan BJ. Initiation and Maintenance of Low‐Dose Transdermal Testosterone in Non‐Binary Individuals: A Retrospective Audit. Clinical Endocrinology. 2026. doi:10.1111/cen.70110

BibTeX
@article{WardSmith2026,
  author = {Ward-Smith, Eli and Cheung, Ada S and Locke, Peter and Zwickl, Sav and Nolan, Brendan J},
  title = {Initiation and Maintenance of Low‐Dose Transdermal Testosterone in Non‐Binary Individuals: A Retrospective Audit},
  journal = {Clinical Endocrinology},
  year = {2026},
  doi = {10.1111/cen.70110}
}
Kostenlos starten →